NCT02644018

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.

Double Blind Randomized Placebo-controlled Multicenter Study to Evaluate Clinical Efficacy and Safety of Ingavirin®, Capsules 30 mg, in 3-6 Years Old Patients With Influenza and Other Acute Respiratory Viral Infections in the Course of Standard Therapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 190 (actual)
• Sponsor: Valenta Pharm JSC · Industry
• Sex: All
• Age: 3 Years – 6 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Ingavirin ® dosed 30 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in the course of standard therapy in 3-6 years old patients.

Conditions

• Common Cold
• Influenza

Interventions

Type	Name	Description
DRUG	Imidazolyl ethanamide pentandioic acid
DRUG	placebo

Timeline

• Start date: 2016-01-01
• Primary completion: 2016-05-01
• Completion: 2016-05-01
• First posted: 2015-12-31
• Last updated: 2016-06-09

Locations

13 sites across 1 country: Russia